Physician profile

Thomas E Hamilton

Family Medicine · Lawrenceburg, KY

NPI 1386674703

$6,594.50

in general payments reported to CMS, 2019-2025

42 companies · $404 in 2025

The $404 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,745.52
Education$84.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $926.95 2021-2025
Glaxosmithkline, LLC. $891.00 2019-2025 Trelegy Ellipta, Arexvy, Shingrix
Lilly USA, LLC $590.87 2019-2025 Jardiance, Mounjaro, Zepbound
Janssen Pharmaceuticals, INC $585.80 2019-2022
Novo Nordisk INC $565.65 2019-2025 Ozempic, Rybelsus, Wegovy
Pfizer INC. $497.84 2019-2024
Astrazeneca Pharmaceuticals Lp $348.90 2019-2025 Airsupra, Farxiga
Astellas Pharma US INC $267.56 2019-2025 Veozah, Myrbetriq
Takeda Pharmaceuticals U.S.A., INC. $246.38 2021-2023 Gattex
Boehringer Ingelheim Pharmaceuticals, INC. $219.80 2019-2024 Synjardy, Jardiance
Allergan, INC. $177.70 2019-2020
Inspire Medical Systems, INC. $169.11 2024 Inspire
Phathom Pharmaceuticals, INC. $111.44 2024-2025 Voquezna
Amarin Pharma, INC. $82.62 2019-2021
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $72.84 2020-2024 Trulance, Xifaxan
Show all 42 companies
CompanyGeneral paymentsYearsTop products
Sanofi-Aventis U.S. LLC $66.33 2020-2023
Novartis Pharmaceuticals Corporation $64.63 2019-2021
Bayer Healthcare Pharmaceuticals INC. $64.21 2021-2024
Almatica Pharma LLC $61.04 2022-2024 Loreev Xr, Sertraline Hcl
Biohaven Pharmaceutical Holding Company Ltd. $55.61 2022
Esperion Therapeutics, INC. $45.26 2020-2021
Corcept Therapeutics $43.79 2021-2024 Korlym
Abbott Laboratories $43.00 2021-2023 Freestyle Libre
Vanda Pharmaceuticals INC. $33.12 2021-2025 Fanapt
Sunovion Pharmaceuticals INC. $32.48 2021-2022
Eisai INC. $31.87 2020-2023
Biohaven Pharmaceuticals, INC. $31.78 2021
E.R. Squibb & Sons, L.L.C. $27.05 2020-2021
Xeris Pharmaceuticals, INC. $21.73 2022
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $20.90 2022
Chiesi USA, INC. $19.23 2024 Mycapssa
Kowa Pharmaceuticals America, INC. $19.01 2023 Seglentis
Bausch Health US, LLC $18.72 2020
Amgen INC. $18.31 2019
Ultragenyx Pharmaceutical INC. $18.29 2021
Pacira Therapeutics, INC. $17.79 2020
Axsome Therapeutics, INC. $15.08 2022
Idorsia Pharmaceuticals US INC $14.78 2023 Quviviq
Hologic Sales and Service, LLC $14.50 2023 Thinprep 2000 Processor
Teva Pharmaceuticals USA, INC. $14.47 2024 Ajovy
Assertio Therapeutics, INC. $13.93 2019
Horizon Therapeutics Plc $13.13 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Thomas E Hamilton

$6,594.50

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbvie INC.
Context
The $404 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/198584/thomas-e-hamilton

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.